Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Assessing tuberculosis control priorities in high-burden settings: a modelling approach.

Vesga JF, Hallett TB, Reid MJA, Sachdeva KS, Rao R, Khaparde S, Dave P, Rade K, Kamene M, Omesa E, Masini E, Omale N, Onyango E, Owiti P, Karanja M, Kiplimo R, Alexandru S, Vilc V, Crudu V, Bivol S, Celan C, Arinaminpathy N.

Lancet Glob Health. 2019 May;7(5):e585-e595. doi: 10.1016/S2214-109X(19)30037-3. Epub 2019 Mar 20.

2.

Building a tuberculosis-free world: The Lancet Commission on tuberculosis.

Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci AS, Fekadu E, Fujiwara PI, Hallett TB, Hanson CL, Harrington M, Herbert N, Hopewell PC, Ikeda C, Jamison DT, Khan AJ, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione MC, Sharman A, Small PM, Swaminathan S, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Agins BD, Alexandru S, Andrews JR, Beyeler N, Bivol S, Brigden G, Cattamanchi A, Cazabon D, Crudu V, Daftary A, Dewan P, Doepel LK, Eisinger RW, Fan V, Fewer S, Furin J, Goldhaber-Fiebert JD, Gomez GB, Graham SM, Gupta D, Kamene M, Khaparde S, Mailu EW, Masini EO, McHugh L, Mitchell E, Moon S, Osberg M, Pande T, Prince L, Rade K, Rao R, Remme M, Seddon JA, Selwyn C, Shete P, Sachdeva KS, Stallworthy G, Vesga JF, Vilc V, Goosby EP.

Lancet. 2019 Mar 30;393(10178):1331-1384. doi: 10.1016/S0140-6736(19)30024-8. Epub 2019 Mar 20. Review. No abstract available.

PMID:
30904263
3.

Modelling the impact of effective private provider engagement on tuberculosis control in urban India.

Arinaminpathy N, Deo S, Singh S, Khaparde S, Rao R, Vadera B, Kulshrestha N, Gupta D, Rade K, Nair SA, Dewan P.

Sci Rep. 2019 Mar 7;9(1):3810. doi: 10.1038/s41598-019-39799-7.

4.

Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care.

Subbaraman R, Nathavitharana RR, Mayer KH, Satyanarayana S, Chadha VK, Arinaminpathy N, Pai M.

PLoS Med. 2019 Feb 27;16(2):e1002754. doi: 10.1371/journal.pmed.1002754. eCollection 2019 Feb.

5.

The Importance of Heterogeneity to the Epidemiology of Tuberculosis.

Trauer JM, Dodd PJ, Gomes MGM, Gomez GB, Houben RM, McBryde ES, Melsew YA, Menzies NA, Arinaminpathy N, Shrestha S, Dowdy DW.

Clin Infect Dis. 2018 Nov 1. doi: 10.1093/cid/ciy938. [Epub ahead of print]

6.

A longitudinal review of national HIV policy and progress made in health facility implementation in Eastern Zimbabwe.

Tlhajoane M, Masoka T, Mpandaguta E, Rhead R, Church K, Wringe A, Kadzura N, Arinaminpathy N, Nyamukapa C, Schur N, Mugurungi O, Skovdal M, Eaton JW, Gregson S.

Health Res Policy Syst. 2018 Sep 21;16(1):92. doi: 10.1186/s12961-018-0358-1.

7.

Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.

Fu H, Lin HH, Hallett TB, Arinaminpathy N.

Vaccine. 2018 Sep 18;36(39):5902-5909. doi: 10.1016/j.vaccine.2018.08.019. Epub 2018 Aug 22.

PMID:
30143270
8.

Management of tuberculosis by healthcare practitioners in Pakistan: A systematic review.

Braham CA, White PJ, Arinaminpathy N.

PLoS One. 2018 Jun 21;13(6):e0199413. doi: 10.1371/journal.pone.0199413. eCollection 2018.

9.

The impact of stratified immunity on the transmission dynamics of influenza.

Yuan HY, Baguelin M, Kwok KO, Arinaminpathy N, van Leeuwen E, Riley S.

Epidemics. 2017 Sep;20:84-93. doi: 10.1016/j.epidem.2017.03.003. Epub 2017 Mar 12.

10.

Estimating Direct and Indirect Protective Effect of Influenza Vaccination in the United States.

Arinaminpathy N, Kim IK, Gargiullo P, Haber M, Foppa IM, Gambhir M, Bresee J.

Am J Epidemiol. 2017 Jul 1;186(1):92-100. doi: 10.1093/aje/kwx037.

11.

Estimating tuberculosis incidence from primary survey data: a mathematical modeling approach.

Pandey S, Chadha VK, Laxminarayan R, Arinaminpathy N.

Int J Tuberc Lung Dis. 2017 Apr 1;21(4):366-374. doi: 10.5588/ijtld.16.0182.

12.

Counting the lives saved by DOTS in India: a model-based approach.

Mandal S, Chadha VK, Laxminarayan R, Arinaminpathy N.

BMC Med. 2017 Mar 3;15(1):47. doi: 10.1186/s12916-017-0809-5.

13.

Tuberculosis burden in India's private sector - Authors' reply.

Arinaminpathy N, Dewan P.

Lancet Infect Dis. 2016 Dec;16(12):1329. doi: 10.1016/S1473-3099(16)30456-X. Epub 2016 Nov 15. No abstract available.

PMID:
27998591
14.

Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines.

Subramanian R, Graham AL, Grenfell BT, Arinaminpathy N.

PLoS Comput Biol. 2016 Dec 15;12(12):e1005204. doi: 10.1371/journal.pcbi.1005204. eCollection 2016 Dec.

15.

The number of privately treated tuberculosis cases in India: an estimation from drug sales data.

Arinaminpathy N, Batra D, Khaparde S, Vualnam T, Maheshwari N, Sharma L, Nair SA, Dewan P.

Lancet Infect Dis. 2016 Nov;16(11):1255-1260. doi: 10.1016/S1473-3099(16)30259-6. Epub 2016 Aug 25.

16.

Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.

Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A.

Lancet Glob Health. 2016 Nov;4(11):e816-e826. doi: 10.1016/S2214-109X(16)30265-0. Epub 2016 Oct 6.

17.

Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models.

Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Lin HH, Wu CY, Mandal S, Pandey S, Suen SC, Bendavid E, Azman AS, Dowdy DW, Bacaër N, Rhines AS, Feldman MW, Handel A, Whalen CC, Chang ST, Wagner BG, Eckhoff PA, Trauer JM, Denholm JT, McBryde ES, Cohen T, Salomon JA, Pretorius C, Lalli M, Eaton JW, Boccia D, Hosseini M, Gomez GB, Sahu S, Daniels C, Ditiu L, Chin DP, Wang L, Chadha VK, Rade K, Dewan P, Hippner P, Charalambous S, Grant AD, Churchyard G, Pillay Y, Mametja LD, Kimerling ME, Vassall A, White RG.

Lancet Glob Health. 2016 Nov;4(11):e806-e815. doi: 10.1016/S2214-109X(16)30199-1. Epub 2016 Oct 6.

18.

Outbreak of Middle East Respiratory Syndrome at Tertiary Care Hospital, Jeddah, Saudi Arabia, 2014.

Hastings DL, Tokars JI, Abdel Aziz IZ, Alkhaldi KZ, Bensadek AT, Alraddadi BM, Jokhdar H, Jernigan JA, Garout MA, Tomczyk SM, Oboho IK, Geller AI, Arinaminpathy N, Swerdlow DL, Madani TA.

Emerg Infect Dis. 2016 May;22(5):794-801. doi: 10.3201/eid2205.151797.

19.

Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.

Nair SA, Raizada N, Sachdeva KS, Denkinger C, Schumacher S, Dewan P, Kulsange S, Boehme C, Paramsivan CN, Arinaminpathy N.

PLoS One. 2016 Feb 26;11(2):e0150054. doi: 10.1371/journal.pone.0150054. eCollection 2016.

20.

Understanding the incremental value of novel diagnostic tests for tuberculosis.

Arinaminpathy N, Dowdy D.

Nature. 2015 Dec 3;528(7580):S60-7. doi: 10.1038/nature16045.

21.

The Global Drug Facility as an intervention in the market for tuberculosis drugs.

Arinaminpathy N, Cordier-Lassalle T, Lunte K, Dye C.

Bull World Health Organ. 2015 Apr 1;93(4):237-248A. doi: 10.2471/BLT.14.147256. Epub 2015 Mar 3.

22.

The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.

Sachdeva KS, Raizada N, Gupta RS, Nair SA, Denkinger C, Paramasivan CN, Kulsange S, Thakur R, Dewan P, Boehme C, Arinaminpathy N.

PLoS One. 2015 Jul 1;10(7):e0131438. doi: 10.1371/journal.pone.0131438. eCollection 2015.

23.

Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.

Sachdeva KS, Raizada N, Sreenivas A, Van't Hoog AH, van den Hof S, Dewan PK, Thakur R, Gupta RS, Kulsange S, Vadera B, Babre A, Gray C, Parmar M, Ghedia M, Ramachandran R, Alavadi U, Arinaminpathy N, Denkinger C, Boehme C, Paramasivan CN.

PLoS One. 2015 May 21;10(5):e0126065. doi: 10.1371/journal.pone.0126065. eCollection 2015.

24.

Seven challenges in modeling pathogen dynamics within-host and across scales.

Gog JR, Pellis L, Wood JL, McLean AR, Arinaminpathy N, Lloyd-Smith JO.

Epidemics. 2015 Mar;10:45-8. doi: 10.1016/j.epidem.2014.09.009. Epub 2014 Sep 30.

25.

Transmission modeling and health systems: the case of TB in India.

Mandal S, Arinaminpathy N.

Int Health. 2015 Mar;7(2):114-20. doi: 10.1093/inthealth/ihv004.

PMID:
25733561
26.

Contact heterogeneity, rather than transmission efficiency, limits the emergence and spread of canine influenza virus.

Dalziel BD, Huang K, Geoghegan JL, Arinaminpathy N, Dubovi EJ, Grenfell BT, Ellner SP, Holmes EC, Parrish CR.

PLoS Pathog. 2014 Oct 23;10(10):e1004455. doi: 10.1371/journal.ppat.1004455. eCollection 2014 Oct.

27.

HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations.

Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, Tatem AJ, Sousa JD, Arinaminpathy N, Pépin J, Posada D, Peeters M, Pybus OG, Lemey P.

Science. 2014 Oct 3;346(6205):56-61. doi: 10.1126/science.1256739. Epub 2014 Oct 2.

28.

The path of least resistance: aggressive or moderate treatment?

Kouyos RD, Metcalf CJ, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, Arinaminpathy N, Bogich TL, Bonhoeffer S, Brower C, Chi-Johnston G, Cohen T, Day T, Greenhouse B, Huijben S, Metlay J, Mideo N, Pollitt LC, Read AF, Smith DL, Standley C, Wale N, Grenfell B.

Proc Biol Sci. 2014 Nov 7;281(1794):20140566. doi: 10.1098/rspb.2014.0566.

29.

The Global Drug Facility and its role in the market for tuberculosis drugs.

Arinaminpathy N, Cordier-Lassalle T, Vijay A, Dye C.

Lancet. 2013 Oct 19;382(9901):1373-9. doi: 10.1016/S0140-6736(13)60896-X. Epub 2013 May 29.

PMID:
23726162
30.

Self-boosting vaccines and their implications for herd immunity.

Arinaminpathy N, Lavine JS, Grenfell BT.

Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20154-9. doi: 10.1073/pnas.1209683109. Epub 2012 Nov 19.

31.

Size and complexity in model financial systems.

Arinaminpathy N, Kapadia S, May RM.

Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18338-43. doi: 10.1073/pnas.1213767109. Epub 2012 Oct 22.

32.

Unifying the spatial epidemiology and molecular evolution of emerging epidemics.

Pybus OG, Suchard MA, Lemey P, Bernardin FJ, Rambaut A, Crawford FW, Gray RR, Arinaminpathy N, Stramer SL, Busch MP, Delwart EL.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15066-71. doi: 10.1073/pnas.1206598109. Epub 2012 Aug 27.

33.

Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza.

Arinaminpathy N, Ratmann O, Koelle K, Epstein SL, Price GE, Viboud C, Miller MA, Grenfell BT.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3173-7. doi: 10.1073/pnas.1113342109. Epub 2012 Feb 7.

34.

Transmission and control in an institutional pandemic influenza A(H1N1) 2009 outbreak.

Arinaminpathy N, Raphaely N, Saldana L, Hodgekiss C, Dandridge J, Knox K, McCarthy ND.

Epidemiol Infect. 2012 Jun;140(6):1102-10. doi: 10.1017/S0950268811001518. Epub 2011 Aug 23.

PMID:
21859502
35.

A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model.

McCaw JM, Arinaminpathy N, Hurt AC, McVernon J, McLean AR.

PLoS Comput Biol. 2011 Apr;7(4):e1002026. doi: 10.1371/journal.pcbi.1002026. Epub 2011 Apr 28.

36.

Dynamics of glycoprotein charge in the evolutionary history of human influenza.

Arinaminpathy N, Grenfell B.

PLoS One. 2010 Dec 30;5(12):e15674. doi: 10.1371/journal.pone.0015674.

37.

Insights into the evolution and emergence of a novel infectious disease.

Kubiak RJ, Arinaminpathy N, McLean AR.

PLoS Comput Biol. 2010 Sep 30;6(9). pii: e1000947. doi: 10.1371/journal.pcbi.1000947.

38.

Health in financial crises: economic recession and tuberculosis in Central and Eastern Europe.

Arinaminpathy N, Dye C.

J R Soc Interface. 2010 Nov 6;7(52):1559-69. doi: 10.1098/rsif.2010.0072. Epub 2010 Apr 28.

39.

Systemic risk: the dynamics of model banking systems.

May RM, Arinaminpathy N.

J R Soc Interface. 2010 May 6;7(46):823-38. doi: 10.1098/rsif.2009.0359. Epub 2009 Oct 28.

40.

Evolution and emergence of novel human infections.

Arinaminpathy N, McLean AR.

Proc Biol Sci. 2009 Nov 22;276(1675):3937-43. doi: 10.1098/rspb.2009.1059. Epub 2009 Aug 19.

41.

Logistics of control for an influenza pandemic.

Arinaminpathy N, McLean AR.

Epidemics. 2009 Jun;1(2):83-8. doi: 10.1016/j.epidem.2009.04.001. Epub 2009 Apr 14.

PMID:
21352754
42.
43.

Antiviral treatment for the control of pandemic influenza: some logistical constraints.

Arinaminpathy N, McLean AR.

J R Soc Interface. 2008 May 6;5(22):545-53.

Supplemental Content

Loading ...
Support Center